MTMT-ben szereplő publikációk tallózása szerző szerint "Torok S"

A találatok rendezése: Rendezés: Találatok:

  • Apelin promotes lymphangiogenesis and lymph node metastasis 
    Berta, Judit; Hoda MA; Laszlo, Viktoria; Rozsas A; Garay, Tamás; Torok S; Grusch M; Berger W; Paku, Sándor; Rényi-Vámos, Ferenc István; Masri B; Tóvári, József; Groger M; Klepetko W; Hegedűs, Balázs; Döme, Balázs (2014)
    Whereas the role of the G-protein-coupled APJ receptor and its ligand, apelin, in angiogenesis has been well documented, the ability of the apelin/APJ system to induce lymphangiogenesis and lymphatic metastasis has been ...
  • Erythropoietin receptor expression is a potential prognostic factor in human lung adenocarcinoma 
    Rozsas A; Berta, Judit; Rojko L; Horvath LZ; Keszthelyi M; Kenessey, István; Laszlo, Viktoria; Berger W; Grusch M; Hoda MA; Torok S; Klepetko W; Rényi-Vámos, Ferenc István; Hegedűs, Balázs; Döme, Balázs; Tóvári, József (2013)
    Recombinant human erythropoietins (rHuEPOs) are used to treat cancer-related anemia. Recent preclinical studies and clinical trials, however, have raised concerns about the potential tumor-promoting effects of these drugs. ...
  • Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors 
    Torok S; Rezeli M; Kelemen O; Vegvari A; Watanabe K; Sugihara Y; Tisza A; Marton T; Kovacs I; Tovari J; Laszlo V; Helbich TH; Hegedűs, Balázs; Klikovits T; Hoda MA; Klepetko W; Paku S; Marko-Varga G; Dome B (2017)
    Resistance mechanisms against antiangiogenic drugs are unclear. Here, we correlated the antitumor and antivascular properties of five different antiangiogenic receptor tyrosine kinase inhibitors (RTKIs) (motesanib, pazopanib, ...